Research Article

Expression of LGR5, FZD7, TROY, and MIST1 in Perioperatively Treated Gastric Carcinomas and Correlation with Therapy Response

Table 2

Correlation of LGR5 and MIST1 expression in primary resected gastric cancer and pretherapeutic biopsies, respectively, with tumor regression.

ValidPrimary resected tumorPretherapeutic biopsy
LGR5 score 0-6MIST1 score 0-6
Low (0-4)High (5-6)Negative (0)Positive (2-6)
(%)(%)(%)(%)(%)

Vital tumor residuals(1)101<0.001#230.048
 <Median (0-54%)59(49.6)34(79.1)9(20.9)9(100.0)0(0.0)
 ≥Median (55-100%)60(50.4)24(41.4)34(58.6)8(57.1)6(42.9)
Vital tumor residuals(2)101<0.001#230.012
 Quartile 1 (0-4%)23(19.3)8(100.0)0(0.0)3(100.0)0(0.0)
 Quartile 2 (5-54%)36(30.3)26(74.3)9(25.7)6(100.0)0(0.0)
 Quartile 3 (55-89%)29(24.4)14(50.0)14(50.0)4(80.0)1(20.0)
 Quartile 4 (90-100%)31(26.1)10(33.3)20(66.7)4(44.4)5(55.6)
Becker regression score(2)101<0.001#230.046
 1a13(10.9)2(100.0)0(0.0)
 1b25(21.0)19(82.6)4(17.4)2(100.0)0(0.0)
 219(16.0)13(72.2)5(27.8)5(100.0)0(0.0)
 362(52.1)26(43.3)34(56.7)8(57.1)6(42.9)

(1)Fisher’s exact test; (2)Kendall’s tau test; #significant after multiple testing.